A Berlin-based research group led by Charité - Universitätsmedizin Berlin has succeeded in simulating SARS-CoV-2 infection in human lungs and has gained important insights into the mechanism of infection. Using living lung samples, they were able to show that the virus is capable of directly infecting the cells of the human alveoli to only a very…
On May 31, 2022, the Digital Health Accelerator Program of the Berlin Institute of Health at Charité (BIH) celebrated its fifth birthday at Demo Day 2022. The entertaining program included presentations by successful grantees and partners, as well as pitches by the seven 2022 newly funded teams of physicians and researchers from Charité -…
As a manufacturer of AI-based software for predicting complications after serious heart surgery, x-cardiac GmbH has successfully completed the certification of its quality management system according to ISO 13485. (German Press Release)
The suspicion of preeclampsia during pregnancy only ends with serious complications in a few cases. With the help of machine learning, researchers at the Charité - Universitätsmedizin Berlin, funded by the Digital Accelerator, have developed a model that can predict the risk of complications much better than the clinical parameters used to date.
On February 15, the 2022 cohort of the BIH Digital Health Accelerator (DHA) kicked off with seven new project teams.
We are happy that our BIH DHA program is featured the international Newsweek magazine about how Berlin leads the way in developing and piloting artificial intelligence solutions in the health sector.
Observations from around the globe suggest that the Omicron variant of the SARS-CoV-2 coronavirus is much more infectious than its predecessor, Delta. But on the other hand, Omicron infections seem to cause milder disease: Hospital admissions and the number of deaths have increased only moderately compared to the huge rise in the number of cases.
Scientists from the Berlin Institute of Health at Charité (BIH), together with colleagues from Charité – Universitätsmedizin Berlin and the university hospitals in Bonn and Aachen, have found a type of immune cells that is particularly active in severely ill COVID-19 patients. The CD16 positive T cells have an increased cytotoxic effect, especially…
The clinical phase II trial CATCOVID initiated by the Berlin Institute of Health at Charité (BIH) has cleared the final regulatory hurdles with the receipt of a positive ethics committee vote and with approval from the Federal Institute for Drugs and Medical Devices (BfArM), enrolling its first patient this week at University of Leipzig Medical…
